The SEQUOIA trial’s Arm C has provided groundbreaking data for high-risk patients with chronic lymphocytic leukemia (CLL) and deletion 17p (del 17p), a group traditionally excluded from chemotherapy-based regimens. This dedicated cohort study followed over 100 patients with TP53 aberrations for a span of 5 years, showcasing the effectiveness of zanubrutinib monotherapy in this complex patient population. By acknowledging the need for specialized treatment approaches for del 17p patients due to their poor response to conventional therapies, the trial design has paved the way for a shift in CLL management strategies.
Achieving a remarkable 72% progression-free survival rate at the 5-year mark, zanubrutinib has emerged as a game-changer in the treatment of high-risk CLL, showing comparable outcomes to TP53 wild-type patients and establishing continuous monotherapy as a viable option for these highest-risk individuals. The SEQUOIA Arm C findings have not only altered the treatment landscape for CLL patients with del 17p but have also instilled confidence in oncologists when managing this historically challenging group. With zanubrutinib now recognized as a highly effective therapeutic choice for the most at-risk CLL patients, the future looks promising for improved outcomes and long-term disease control.
Read more from targetedonc.com